Maree T Smith Selected Research

WL 19

1/2017	Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia - A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist.
10/2013	A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.
5/2013	Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maree T Smith Research Topics

Disease

40	Pain (Aches) 10/2022 - 03/2002
26	Neuralgia (Stump Neuralgia) 01/2022 - 11/2005
21	Hyperalgesia 11/2021 - 08/2003
11	Cancer Pain 10/2022 - 08/2003
9	Hypersensitivity (Allergy) 12/2019 - 11/2011
8	Constipation 10/2022 - 01/2012
6	Respiratory Insufficiency (Respiratory Failure) 10/2022 - 04/2014
6	Neoplasms (Cancer) 12/2019 - 12/2013
5	Diabetic Neuropathies (Diabetic Neuropathy) 06/2016 - 05/2010
4	Vomiting 10/2022 - 06/2011
4	Nausea 10/2022 - 06/2011
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 12/2013
4	Intractable Pain 10/2020 - 10/2013
4	Breast Neoplasms (Breast Cancer) 12/2019 - 01/2016
3	Low Back Pain (Lumbago) 12/2020 - 07/2018
3	Prostatic Neoplasms (Prostate Cancer) 10/2020 - 05/2013
3	Neuroinflammatory Diseases 10/2020 - 11/2014
3	Chronic Pain 01/2018 - 04/2010
3	Critical Illness (Critically Ill) 03/2013 - 11/2012
2	Multiple Sclerosis 01/2022 - 02/2018
2	Alzheimer Disease (Alzheimer's Disease) 10/2020 - 10/2014
2	Wounds and Injuries (Trauma) 01/2020 - 04/2014
2	Neoplasm Metastasis (Metastasis) 01/2017 - 10/2013
2	Postherpetic Neuralgia 02/2016 - 05/2010
2	Inflammation (Inflammations) 06/2012 - 05/2007
2	Hyperglycemia 05/2011 - 03/2011
1	Opioid-Related Disorders (Opiate Addiction) 10/2022
1	Pruritus (Itching) 10/2022
1	Acute Pain 10/2022
1	Nociceptive Pain 01/2020
1	Opiate Overdose 01/2020
1	Chagas Disease (American Trypanosomiasis) 01/2019

Drug/Important Bio-Agent (IBA)

27	Analgesics (Analgesic Drugs)IBA 10/2022 - 11/2011
22	Morphine (MS Contin)FDA LinkGeneric 10/2022 - 08/2003
22	Opioid Analgesics (Opioids)IBA 10/2022 - 05/2007
12	Pharmaceutical PreparationsIBA 01/2021 - 01/2008
6	Ketamine FDA LinkGeneric 10/2022 - 05/2007
6	Pregabalin (Lyrica)FDA Link 01/2021 - 05/2010
5	Gabapentin (Neurontin)FDA LinkGeneric 11/2021 - 05/2013
5	Type 2 Angiotensin ReceptorIBA 01/2015 - 05/2013
4	Amitriptyline (Elavil)FDA LinkGeneric 11/2021 - 05/2013
4	Meloxicam (Mobic)FDA LinkGeneric 11/2021 - 05/2013
4	salicylhydroxamic acid (SHAM)IBA 09/2020 - 01/2016
4	Angiotensin IIIBA 01/2017 - 10/2013
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 12/2014
3	Dihydrotachysterol (AT 10)IBA 01/2021 - 10/2020
3	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2021 - 07/2012
3	2S)- 4- amino- N- (1'- carbamoyl- 2'- phenylethyl)- 2- (4''- methyl- 1''- naphthalenesulfonylamino)butanamide (1'SIBA 12/2020 - 01/2018
3	Hydromorphone (Dilaudid)FDA LinkGeneric 10/2020 - 04/2010
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2020 - 06/2015
3	Opioid Receptors (Opioid Receptor)IBA 03/2020 - 03/2011
3	Narcotic Antagonists (Opioid Antagonists)IBA 03/2020 - 05/2013
3	1,2,5-oxadiazole 2-oxideIBA 01/2019 - 09/2015
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 09/2015
3	WL 19IBA 01/2017 - 05/2013
3	EMA400IBA 02/2016 - 05/2013
3	Oxycodone (Oxycontin)FDA LinkGeneric 07/2015 - 12/2007
3	Type 1 Angiotensin ReceptorIBA 04/2014 - 10/2013
2	Thioctic Acid (Lipoic Acid)IBA 01/2022 - 06/2015
2	Glycine Plasma Membrane Transport ProteinsIBA 01/2021 - 10/2020
2	Ion Channels (Ion Channel)IBA 10/2020 - 01/2018
2	LigandsIBA 03/2020 - 10/2008
2	Somatostatin Receptors (Somatostatin Receptor)IBA 09/2019 - 01/2018
2	CytokinesIBA 07/2018 - 04/2010
2	Proteins (Proteins, Gene)FDA Link 02/2018 - 01/2018
2	Naloxone (Narcan)FDA LinkGeneric 01/2017 - 05/2013
2	Angiotensin II Type 2 Receptor BlockersIBA 02/2016 - 04/2014
2	PD 123319IBA 01/2014 - 05/2013
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 07/2012 - 11/2009
2	Xen2174IBA 11/2009 - 11/2005
1	ProdrugsIBA 01/2022
1	EsterasesIBA 01/2022
1	EstersIBA 01/2022
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2021
1	LipidsIBA 10/2020
1	Amyloid (Amyloid Fibrils)IBA 10/2020
1	Glial Fibrillary Acidic ProteinIBA 10/2020
1	Charcoal (Charbon)IBA 03/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 03/2020
1	endomorphin 2IBA 03/2020
1	Castor Oil (Oil, Castor)IBA 03/2020
1	Central Nervous System Depressants (CNS Depressants)IBA 01/2020
1	Respiratory System Agents (Respiratory Stimulants)IBA 01/2020
1	Stavudine (Zerit)FDA LinkGeneric 04/2019
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2019
1	benzonidazole (benznidazole)IBA 01/2019
1	Antineoplastic Agents (Antineoplastics)IBA 01/2019
1	Antiparasitic Agents (Antiparasitics)IBA 01/2019
1	Buprenorphine (Subutex)FDA LinkGeneric 10/2018
1	D-Penicillamine (2,5)- EnkephalinIBA 10/2018
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 02/2018
1	InflammasomesIBA 02/2018
1	NLR ProteinsIBA 02/2018

Therapy/Procedure

10	Analgesia 01/2020 - 10/2008
5	Therapeutics 01/2020 - 10/2014
4	Drug Therapy (Chemotherapy) 01/2021 - 12/2013
3	Oral Administration 10/2020 - 06/2012
2	Punctures 12/2020 - 05/2018
2	Intravenous Administration 04/2013 - 06/2012
1	Spinal Injections 01/2019